LATEST ONCOPRESCRIBE UPDATES
Late Breaking Abstract – ASCO 2022: Survival Benefit with TRODELVY® in Hormone Receptor Positive/HER2-Negative Metastatic Breast Cancer
Late Breaking Abstract – ASCO 2022: Adagrasib in KRAS G12C Mutated Non Small Cell Lung Cancer
Late Breaking Abstract – ASCO 2022: Adjuvant Radiotherapy May Be Omitted in Select Patients with Luminal A Breast Cancer
Late Breaking Abstract – ASCO 2022: Circulating Tumor DNA in the Peripheral Blood Can Guide Adjuvant Therapy Decision in Stage II Colon Cancer
Late Breaking Abstract – ASCO 2022: IMBRUVICA® plus Bendamustine and Rituximab for Older Patients with Untreated Mantle Cell Lymphoma
FDA Approves OPDIVO® Combination for Advanced Esophageal Carcinoma
Consider Guideline-Recommended Biomarker Testing as an Integral Component of NSCLC Care
FDA Approves KYMRIAH® for Relapsed or Refractory Follicular Lymphoma
